Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction

Metronomics: Intrinsic Anakoinosis Modulator?

(2018) André Nicolas et al.   Frontiers in Pharmacology

Nucleolar caspase-2: Protecting us from DNA damage

(2017) Kenneth J. O’Byrne et al.   JOURNAL OF CELL BIOLOGY

NPM1 directs PIDDosome-dependent caspase-2 activation in the nucleolus

(2017) Kiyohiro Ando et al.   JOURNAL OF CELL BIOLOGY

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial

(2017) I. Walter et al.   MEDICAL ONCOLOGY

Slow release of etoposide from dextran conjugation shifts etoposide activity from cytotoxicity to differentiation: A promising tool for dosage control in anticancer metronomic therapy

(2017) Milena De Nicola et al.   Nanomedicine-Nanotechnology Biology and Medicine

The DNA damage-induced cell death response: a roadmap to kill cancer cells

(2016) Sonja Matt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

(2016) Tze-Sian Chan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach

(2016) L Flanagan et al.   Cell Death & Disease

DNA Damage Response and Immune Defense: Links and Mechanisms

(2016) Rania Nakad et al.   Frontiers in Genetics

Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma

(2015) Peter Ugocsai et al.   BRITISH JOURNAL OF HAEMATOLOGY

Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

(2015) Irina Kareva et al.   CANCER LETTERS

DNA Damage: A Sensible Mediator of the Differentiation Decision in Hematopoietic Stem Cells and in Leukemia

(2015) Cary Weiss et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial

(2015) C. Hart et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where

(2015) Ioannis S. Pateras et al.   PHARMACOLOGY & THERAPEUTICS

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine

(2015) Sébastien Benzekry et al.   SEMINARS IN CANCER BIOLOGY

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence

(2015) Sabine Taschner-Mandl et al.   Oncotarget

DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation

(2015) Christopher P. Allen et al.   Frontiers in Oncology

Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model

(2014) Junjie Wu et al.   CANCER LETTERS

Old, new and emerging functions of caspases

(2014) S Shalini et al.   CELL DEATH AND DIFFERENTIATION

Assessment of metal contaminants in non-small cell lung cancer by EDX microanalysis

(2014) M. Scimeca et al.   EUROPEAN JOURNAL OF HISTOCHEMISTRY

Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia

(2014) S. Thomas et al.   HAEMATOLOGICA

Expression of caspase-3 predicts prognosis in advanced noncardia gastric cancer

(2014) Sousana Amptoulach et al.   MEDICAL ONCOLOGY

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

(2014) Antonina V. Kurtova et al.   NATURE

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells

(2012) Eddy Pasquier et al.   ANGIOGENESIS

Redox modulation of the DNA damage response

(2012) Fanny Caputo et al.   BIOCHEMICAL PHARMACOLOGY

DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis

(2012) Wynand P. Roos et al.   CANCER LETTERS

Host Immune Defense Peptide LL-37 Activates Caspase-Independent Apoptosis and Suppresses Colon Cancer

(2012) S. X. Ren et al.   CANCER RESEARCH

Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs

(2011) Luis I. Toledo et al.   Molecular Oncology

Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy

(2011) Qian Huang et al.   NATURE MEDICINE

Regulation of cell differentiation by the DNA damage response

(2011) Mara H. Sherman et al.   TRENDS IN CELL BIOLOGY

The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide

(2010) Viviana R. Rozados et al.   ONCOLOGY RESEARCH

Apoptotic Cells Activate the "Phoenix Rising" Pathway to Promote Wound Healing and Tissue Regeneration

(2010) F. Li et al.   Science Signaling

RETRACTED: DNA-PKcs-PIDDosome: A Nuclear Caspase-2-Activating Complex with Role in G2/M Checkpoint Maintenance

(2009) Mingan Shi et al.   CELL

Genotoxic Stress Abrogates Renewal of Melanocyte Stem Cells by Triggering Their Differentiation

(2009) Ken Inomata et al.   CELL

Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3

(2008) Samuel Sidi et al.   CELL